[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100262475":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":24,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":10,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Hypertrophic cardiomyopathy",null,"Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and\u002For cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.",[13],{"name":14,"affiliation":15,"role":16},"Song Lei, MD.&ph.D","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","86-13810532620","clinicalfw@163.com",{"name":14,"role":19,"phone":23,"phoneExt":10,"email":21},"86-18600197655",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fuwai hospital","RECRUITING","Beijing","Beijing Municipality","100037","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40,42],{"name":41,"role":19,"phone":20,"phoneExt":10,"email":21},"Lei Song, MD.& PhD.",{"name":41,"role":19,"phone":23,"phoneExt":10,"email":43},"lsongqd@yahoo.com",{"type":16,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Lei.Song@NCCD","MD.&ph.D","100262475","the-chinese-hypertrophic-cardiomyopathy-studychcs-100262475",false,"NCT02696135","The Chinese Hypertrophic Cardiomyopathy Study(CHCS)","CHCS","Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and\u002For cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM.\n\nExclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.",true,"ALL",{"count":57,"type":58},3000,"ESTIMATED","OBSERVATIONAL","Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF\u002FAHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.",[62],"Cardiomyopathy, Hypertrophic",[64,65,66,67],"hypertrophic cardiomyopathy","clinical outcomes","multi-omics","risk stratification","2018-03-24",{"date":70,"type":71},"2018-03-27","ACTUAL",{"date":73,"type":71},"2011-03-23",{"date":75,"type":58},"2028-12-31",{"name":5,"class":6},1]